Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma
In a closely watched result, Adcentris, a cancer drug sold by the biotech firm Seattle Genetics and the Japanese drug giant Takeda, outperformed traditional chemotherapy in front-line Hodgkin lymphoma, a result that is likely to lead to a broadened approval from the Food and Drug Administration.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:SGEN Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Genetics | Lymphoma | Pharmaceuticals